Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study

J Clin Endocrinol Metab. 2021 May 13;106(6):1750-1760. doi: 10.1210/clinem/dgab079.

Abstract

Context: Psychiatric symptoms are common in Cushing's disease (CD) and seem only partly reversible following treatment.

Objective: To investigate drug dispenses associated to psychiatric morbidity in CD patients before treatment and during long-term follow-up.

Design: Nationwide longitudinal register-based study.

Setting: University Hospitals in Sweden.

Subjects: CD patients diagnosed between 1990 and 2018 (N = 372) were identified in the Swedish Pituitary Register. Longitudinal data was collected from 5 years before, at diagnosis, and during follow-up. Four matched controls per patient were included. Cross-sectional subgroup analysis of 76 patients in sustained remission was also performed.

Main outcome measures: Data from the Swedish Prescribed Drug Register and the Patient Register.

Results: In the 5-year period before and at diagnosis, use of antidepressants (odds ratio [OR] 2.2 [95% confidence interval (CI) 1.3-3.7]) and 2.3 [1.6-3.5]), anxiolytics [2.9 (1.6-5.3) and 3.9 (2.3-6.6)], and sleeping pills [2.1 (1.2-3.7) and 3.8 (2.4-5.9)] was more common in CD than controls. ORs remained elevated at 5-year follow-up for antidepressants [2.4 (1.5-3.9)] and sleeping pills [3.1 (1.9-5.3)]. Proportions of CD patients using antidepressants (26%) and sleeping pills (22%) were unchanged at diagnosis and 5-year follow-up, whereas drugs for hypertension and diabetes decreased. Patients in sustained remission for median 9.3 years (interquartile range 8.1-10.4) had higher use of antidepressants [OR 2.0 (1.1-3.8)] and sleeping pills [2.4 (1.3-4.7)], but not of drugs for hypertension.

Conclusions: Increased use of psychotropic drugs in CD was observed before diagnosis and remained elevated regardless of remission status, suggesting persisting negative effects on mental health. The study highlights the importance of early diagnosis of CD, and the need for long-term monitoring of mental health.

Keywords: Cushing’s syndrome; depression; hypercortisolism; neuropsychiatry; sleeping disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Longitudinal Studies
  • Male
  • Mental Disorders / drug therapy*
  • Mental Disorders / epidemiology
  • Mental Disorders / etiology
  • Middle Aged
  • Morbidity
  • Pituitary ACTH Hypersecretion / complications
  • Pituitary ACTH Hypersecretion / diagnosis
  • Pituitary ACTH Hypersecretion / drug therapy
  • Pituitary ACTH Hypersecretion / epidemiology*
  • Psychotropic Drugs / therapeutic use*
  • Retrospective Studies
  • Sweden / epidemiology

Substances

  • Psychotropic Drugs